<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798793</url>
  </required_header>
  <id_info>
    <org_study_id>WuhanHStomatology</org_study_id>
    <nct_id>NCT05798793</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma</brief_title>
  <acronym>NEOPCOSCC</acronym>
  <official_title>A Multi-Center, Randomized Phase III Study of Neoadjuvant Anti-PD-1 Immunotherapy Plus TP Chemotherapy Versus TP Chemotherapy or Up-Front Surgery in Resectable Locally Advanced Oral Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of Stomatology, Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of Stomatology, Wuhan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1&#xD;
      immunotherapy plus TP chemotherapy compared with TP chemotherapy or up-front surgery in&#xD;
      resectable locally advanced oral squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the basis of preliminary study, this study is to further verify the efficacy and safety of&#xD;
      neoadjuvant anti-PD-1 immunotherapy plus chemotherapy. The further purpose of this study is&#xD;
      to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP&#xD;
      chemotherapy compared with TP chemotherapy or up-front surgery in resectable locally advanced&#xD;
      oral squamous cell carcinoma. And on this basis, the investigators will explore the changes&#xD;
      of the profiles and functions of immune cells within tumors, lymph nodes and peripheral blood&#xD;
      after the experimental interventions, as well as their correlation with the patients'&#xD;
      response and prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival (EFS) Rate on Each Treatment Arm.</measure>
    <time_frame>24 months.</time_frame>
    <description>EFS is the time from the date of randomization to the date of first record of disease progression as defined by RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) on Each Treatment Arm.</measure>
    <time_frame>24 months.</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response.</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Clinical response of tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy, as evaluated by radiographic examinations and defined by RECIST 1.1.&#xD;
Clinical response of tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy, as evaluated by radiographic examinations and defined by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Response.</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Pathologic response of resected tumors and lymph nodes to neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy. Pathologic response is defined as sum of pathologic complete response and major pathologic response. Pathologic complete response is defined as the absence of viable residual tumor in resected specimen. The rate of major pathologic response, defined as &lt;10% residual viable tumor cells in the resected specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs).</measure>
    <time_frame>24 months.</time_frame>
    <description>Number of participants experiencing any sign, symptom, disease, or worsening of preexisting conditions temporally associated with the experimental interventions or irrespective of the experimental interventions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the Level of Circualting Exosomal PD-L1.</measure>
    <time_frame>24 months.</time_frame>
    <description>The level of circulating exosomal PD-L1 at serial time points pre- and on-treatment, as detected by enzyme-linked immunosorbent assay (ELISA).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">309</enrollment>
  <condition>Oral Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Surgery followed by postoperative RT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant TP chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive 2 courses of TP chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive 3 doses of PD-1 blockade and 2 courses of TP chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab plus TP</intervention_name>
    <description>The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.</description>
    <arm_group_label>Neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy</arm_group_label>
    <other_name>SHR-1210 plus Docetaxel, Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP</intervention_name>
    <description>The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.</description>
    <arm_group_label>Neoadjuvant TP chemotherapy</arm_group_label>
    <other_name>Docetaxel, Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically documented oral squamous cell carcinoma (biopsy required).&#xD;
&#xD;
          2. Local advanced oral squamous cell carcinoma (clinical stage T1-2N1-3M0, T3-4aN0-3M0)&#xD;
             with resection option for potential cure, as assessed by a faculty surgeon at Hospital&#xD;
             of Stomatology, Wuhan University.&#xD;
&#xD;
          3. Distant metastasis is excluded by chest CT and emission computed tomograph.&#xD;
&#xD;
          4. Adequate organ function as follows: 1) Leukocyte count ≥ 2,000/mm3; 2) Absolute&#xD;
             neutrophil count ≥ 1,000/mm3; 3) Platelet count ≥ 100,000/mm3; 4) Hemoglobin ≥ 90 g/L;&#xD;
             5) Serum albumin ≥30 g/L; 6) Total bilirubin ≤ 1.5 × upper limit of normal (ULN); 7)&#xD;
             AST (SGOT) and ALT (SGPT) &lt; 2.5 × ULN; 8) ALP ≤ 2.5 × ULN; 9) Prothrombin&#xD;
             time-international normalized ratio ≤ 1.5; 10) Serum creatinine ≤ 1.5 × ULN; 11)&#xD;
             INR/PT≤ 1.5; 12) TSH ≤ ULN.&#xD;
&#xD;
          5. ECOG performance status 0-1.&#xD;
&#xD;
          6. Female patient tested HCG negative in serum or urine within 7 days prior to the start&#xD;
             of investigational product. Both patient and partner must agree to use contraception&#xD;
             prior to study entry and for the duration of study participation and for up to 120&#xD;
             days after the last dose of PD-1 blockade.&#xD;
&#xD;
          7. Patient understands the study regimen, its requirements, risks and discomforts and is&#xD;
             able and willing to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of ≥ 3 grade immune related adverse events (irAEs) or have not recovered to ≤&#xD;
             1 grade irAEs from previous treatment.&#xD;
&#xD;
          2. History of other treatments for cancer, including surgery, chemotherapy, radiotherapy&#xD;
             or molecular targeted therapy within past 5 years.&#xD;
&#xD;
          3. Previous therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other&#xD;
             antibody targeting T cell co-regulatory pathways.&#xD;
&#xD;
          4. Active autoimmune disease or history of refractory autoimmune disease.&#xD;
&#xD;
          5. Active systemic infection requiring therapy.&#xD;
&#xD;
          6. Patients who are receiving psychotropic drug or alcohol/drug abuse.&#xD;
&#xD;
          7. Subjects with concurrent other active malignancies.&#xD;
&#xD;
          8. HIV or untreated active HBV or HCV infections, or vaccinated (HBV, flu, varicella,&#xD;
             etc) within 4 weeks before recruitment.&#xD;
&#xD;
          9. Uncontrollable systemic diseases, including diabetes, hypertension, etc.&#xD;
&#xD;
         10. History of stroke or transient ischemic attack within past 6 months.&#xD;
&#xD;
         11. Distant metastases or inability to resect after physician evaluation.&#xD;
&#xD;
         12. Serious cardiovascular, respiratory, immune system critical disease or other&#xD;
             conditions that the researchers thought might increase the subjects' risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Stomatology, Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Chen, M.D.</last_name>
    <phone>+86 02787686215</phone>
    <email>geraldchan@whu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Stomatology, Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>May 6, 2023</last_update_submitted>
  <last_update_submitted_qc>May 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital of Stomatology, Wuhan University</investigator_affiliation>
    <investigator_full_name>Gang Chen</investigator_full_name>
    <investigator_title>Chief physician, Professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Oral squamous cell carcinoma</keyword>
  <keyword>Anti-PD-1 immunotherapy</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>TP chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

